A cancer patient waiting on chemotherapy approval. A diabetic whose insulin switch sits in a queue. A psychiatrist watching a patient destabilize while paperwork bounces between a clinic and an insurer’s review desk. These are not hypotheticals. According to the American Medical Association’s 2024 Prior Authorization Physician Survey, 94% of physicians say prior authorization delays have directly harmed their patients’ care.
Now the Centers for Medicare and Medicaid Services wants to put a hard clock on those delays. A proposed rule published April 14, 2026, under docket CMS-0062-P, would force health plans to decide standard drug prior authorization requests within 72 hours and urgent requests within 24 hours. The public comment window is open now and closes June 15, 2026, giving patients, doctors, pharmacists, and insurers just days to weigh in on a policy that could reshape prescription access for tens of millions of Americans starting in 2027.
What the proposed rule would require
The central mandate is blunt: plans must say yes or no on a standard drug prior authorization request within 72 hours, and within 24 hours if the request is flagged as urgent. That is a sharp compression. The earlier final rule for non-drug services, CMS-0057-F, gave plans 7 calendar days for standard decisions and 72 hours for expedited ones. For prescription drugs, where a week without coverage can mean a missed chemotherapy cycle, uncontrolled blood sugar, or a psychiatric crisis, CMS is cutting the standard window by more than half.
The rule’s scope goes well beyond Medicare Advantage. CMS would extend electronic prior authorization requirements for drugs to Medicaid fee-for-service programs, Medicaid managed care plans, the Children’s Health Insurance Program (CHIP), and qualified health plan issuers on the federally facilitated exchanges. Together, those programs cover an estimated 170 million people, based on CMS enrollment figures. Traditional Medicare fee-for-service and employer-sponsored plans fall outside this proposal, but the affected programs still represent the largest publicly funded insurance channels in the country.
The proposal also requires public reporting. Plans would need to post summary data on their websites showing how often they approve, deny, or delay drug requests, and how fast they reach decisions. The goal, according to the CMS fact sheet accompanying the proposal, is to let patients compare insurer performance before they enroll and to give regulators a clearer view of plan behavior. Compliance would generally begin in 2027.
In a press release, CMS framed the initiative as part of a broader push to cut administrative burden on clinicians and speed drug access. The agency cited treatment interruptions and hours of back-and-forth documentation as direct consequences of the status quo.
How this builds on the earlier non-drug rule
CMS is not starting from scratch. The CMS-0057-F final rule already established electronic prior authorization standards and decision-time limits for non-drug items and services. Plans that invested in interoperability infrastructure to meet those requirements may find the transition to drug-specific compliance less disruptive. Plans still running manual or fax-based workflows face a steeper climb, and CMS has not published data on how many fall into each category.
The drug proposal uses the same interoperability framework: standardized electronic transactions with consistent data formats for requests and responses. CMS argues that automating routine decisions will reduce the phone calls, faxed forms, and repeated documentation requests that eat up clinical staff time. If implemented as written, the combined drug and non-drug rules would create a more uniform prior authorization environment across federal programs, though timelines would still differ by service type.
The practical question is whether roughly one year from finalization to compliance gives plans and state agencies enough runway. Organizations already operating near the proposed thresholds will absorb the change more easily. Those that are not will need to upgrade systems, retrain staff, and redesign workflows on a compressed schedule.
What physicians, insurers, and patient groups are saying
Physician organizations have pushed for tighter prior authorization timelines for years. The AMA has called prior authorization “a significant barrier to patient care” and has advocated for electronic processing standards and enforceable decision deadlines. The proposed rule tracks closely with those positions, and the AMA’s survey data is among the most frequently cited evidence in the rulemaking record.
Health insurance trade groups, including America’s Health Insurance Plans (AHIP), have historically argued that prior authorization is a necessary check on inappropriate prescribing and a tool for controlling costs. In past rulemaking cycles, industry representatives raised concerns that overly rigid timelines could lead to less thorough clinical review or push plans toward quick denials when documentation is incomplete. Whether those objections surface again in the current comment period will become clearer as the June 15 deadline approaches.
Patient advocacy organizations have added a different kind of evidence. Groups representing people with cancer, diabetes, autoimmune diseases, and serious mental illness have documented cases where prior authorization delays led to disease progression, emergency hospitalizations, or treatment abandonment. A 2022 report from the HHS Office of Inspector General found that Medicare Advantage plans denied 13% of prior authorization requests that actually met Medicare coverage rules. That finding, now nearly four years old, remains one of the most cited data points in the debate and suggests the current system produces a meaningful rate of inappropriate denials even without time pressure.
Unresolved questions that commenters are likely to raise
Several important gaps remain in the published materials, and they point directly to the issues most likely to dominate the comment period.
No baseline data on current decision times. CMS has not released figures on how long plans currently take to process drug prior authorization requests under Medicare Advantage or other affected programs. The AMA survey documents widespread delays from the clinician side, and the HHS OIG report provides denial-rate data that indirectly reflects how the review process functions. But neither source supplies a direct measurement of average plan decision times for drug requests. Without that benchmark, it is hard to know whether the 72-hour and 24-hour windows represent a modest tightening or a wholesale overhaul for most plans.
State Medicaid readiness is unclear. State Medicaid agencies would bear direct compliance obligations under the rule, but as of early June 2026, none have issued public statements about their operational readiness. For underfunded state programs, a roughly one-year implementation window could strain already limited IT and staffing resources. The proposal does not detail how CMS plans to support or monitor state-level implementation beyond the general requirements.
Faster clocks could mean faster denials. This is the most consequential open question. If a plan lacks complete documentation when the deadline arrives, the incentive structure could push it toward rejection rather than approval, shifting the burden to patients and providers to navigate the appeals process. CMS points to transparency requirements and standardized electronic exchanges as safeguards, but the proposal does not spell out specific penalties tied to excessive denial rates or repeated missed deadlines. Commenters from both the physician and patient advocacy communities are likely to press hard on enforcement mechanisms before the window closes.
Traditional Medicare Part D standalone plans are not addressed. The proposal targets Medicare Advantage prescription drug plans, Medicaid, CHIP, and marketplace plans. Enrollees in standalone Part D plans under traditional Medicare are not covered by these requirements, a gap that some commenters may flag given that Part D serves millions of beneficiaries who face similar prior authorization friction.
How to submit a comment before the June 15 deadline
Public comments can be submitted through the federal rulemaking portal at regulations.gov by searching for docket CMS-0062-P. The deadline is June 15, 2026. CMS is required by law to review and respond to substantive comments before issuing a final rule, which means the feedback submitted in the coming days will directly shape whether the 72-hour and 24-hour deadlines survive intact, get modified, or gain additional enforcement teeth.
Anyone enrolled in Medicare Advantage, Medicaid, CHIP, or a marketplace plan has standing to comment. So do physicians, pharmacists, hospital systems, insurers, and state agencies. For a rule that could change how quickly tens of millions of Americans get access to prescribed medications, the comment period is unusually short. Fourteen days is not much time to influence a policy this large, which is exactly why CMS is hearing from stakeholders now.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
